Next 10 |
home / stock / gsk / gsk articles
A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 laws...
On Wednesday, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recomm...
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice will meet this week to consider and recommend wh...
Pfizer Inc (NYSE:PFE) has reportedly secured a major contract with the U.K. to supply millions of doses of its Abrysvo respiratory syncytial virus ...
Gilead Sciences, Inc. (NASDAQ: GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a p...
A bid by GSK Plc (NYSE:GSK) and other pharmaceutical companies to halt over 70,000 lawsuits in Delaware concerning the discontinued heartburn drug ...
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company’s unique business model centered around royaltie...
On Sunday, GSK plc (NYSE:GSK) released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial evaluating Blenrep (belanta...
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results. SAIC reported a 9% ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 08:30:06 ET Jefferies analyst issues BUY recommendation for GSK on July 2, 2024 06:21AM ET. The previous analyst recommendation was Buy. GSK was trading at $38.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes 1 Clinical development program continues to evaluate safety and immunogenicity in adults 18+ with data read-outs expected H2 2024 GSK plc (LSE/NYSE: GSK) today an...
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response New treatment options are needed for patients facing negative impacts to quality-of-life with current standard of care Additional registrational ...